- If you are wondering whether Edwards Lifesciences at around US$79.34 is a bargain or fully priced, you are in the right place for a clear valuation checkup.
- The stock has had a mixed run recently, with a 3.8% decline over the last week and a 4.9% decline over the past month, although the 1 year return sits at 11.9% and longer periods show softer results.
- Recent coverage has focused on Edwards Lifesciences as a key player in medical equipment, which keeps investor attention on how the market is weighing its growth prospects against risks. This context helps explain why the share price may move in response to shifts in sentiment around healthcare spending or product pipelines, even without company specific announcements.
- On Simply Wall St's 6 point valuation checklist, Edwards Lifesciences currently scores 2 out of 6. The sections ahead will break down what different valuation methods say about the stock, before finishing with a more complete way to think about its value.
Edwards Lifesciences scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It is essentially asking what all those future dollars are worth in today’s terms.
For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $1.29b. Analyst estimates and subsequent extrapolations point to free cash flow of $1.55b in 2026, rising in the model to $3.17b by 2035. The later years are based on Simply Wall St extrapolations rather than direct analyst forecasts.
Running these cash flows through the DCF model results in an estimated intrinsic value of about $89.80 per share, compared with a current share price around $79.34. That implies the stock is roughly 11.6% undervalued based on these assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Edwards Lifesciences is undervalued by 11.6%. Track this in your watchlist or portfolio, or discover 59 more high quality undervalued stocks.
Approach 2: Edwards Lifesciences Price vs Earnings
For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of earnings. This makes it a common anchor for comparing stocks in the same sector.
What counts as a “normal” P/E depends on how the market views a company’s growth outlook and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower “fair” multiple.
Edwards Lifesciences currently trades on a P/E of 43.47x. That sits above the Medical Equipment industry average of 27.73x and also above the peer average of 25.92x. On its own, that might suggest the shares are priced at a premium.
Simply Wall St’s Fair Ratio for Edwards Lifesciences is 35.88x. This is a proprietary estimate of what the P/E could be, given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it blends these elements, it can be a more tailored yardstick than simple industry or peer comparisons.
Comparing the Fair Ratio of 35.88x with the current P/E of 43.47x points to the shares trading above this model driven range.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your way to attach a clear story to the numbers, linking your view on Edwards Lifesciences’ future revenue, earnings and margins to a financial forecast and fair value. This is all done through an easy tool on Simply Wall St’s Community page that updates automatically when fresh news or earnings arrive. It also lets you compare that Fair Value with the current share price so you can judge for yourself whether it looks appealing or stretched. One investor might align with the most optimistic analyst view that points to a fair value near US$110, while another leans toward the cautious end around US$84, each building a different but clearly quantified Edwards Lifesciences Narrative.
Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com